MA53665A - Agonistes du récepteur farnésoïde x et leurs utilisations - Google Patents

Agonistes du récepteur farnésoïde x et leurs utilisations

Info

Publication number
MA53665A
MA53665A MA053665A MA53665A MA53665A MA 53665 A MA53665 A MA 53665A MA 053665 A MA053665 A MA 053665A MA 53665 A MA53665 A MA 53665A MA 53665 A MA53665 A MA 53665A
Authority
MA
Morocco
Prior art keywords
farnesoid
receptor agonists
agonists
receptor
Prior art date
Application number
MA053665A
Other languages
English (en)
Other versions
MA53665B1 (fr
Inventor
Karensa L Douglas
Steven P Govek
Andiliy G Lai
Nicholas D Smith
Original Assignee
Metacrine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metacrine Inc filed Critical Metacrine Inc
Publication of MA53665A publication Critical patent/MA53665A/fr
Publication of MA53665B1 publication Critical patent/MA53665B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Biotechnology (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA53665A 2018-09-18 2019-09-17 Agonistes du récepteur farnésoïde x et leurs utilisations MA53665B1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862733006P 2018-09-18 2018-09-18
US201862733004P 2018-09-18 2018-09-18
US201962881560P 2019-08-01 2019-08-01
EP19862391.0A EP3852748B1 (fr) 2018-09-18 2019-09-17 Agonistes du récepteur farnésoïde x et leurs utilisations
PCT/US2019/051603 WO2020061113A1 (fr) 2018-09-18 2019-09-17 Agonistes du récepteur farnésoïde x et leurs utilisations

Publications (2)

Publication Number Publication Date
MA53665A true MA53665A (fr) 2021-07-28
MA53665B1 MA53665B1 (fr) 2025-09-30

Family

ID=69887982

Family Applications (1)

Application Number Title Priority Date Filing Date
MA53665A MA53665B1 (fr) 2018-09-18 2019-09-17 Agonistes du récepteur farnésoïde x et leurs utilisations

Country Status (27)

Country Link
US (4) US11084817B2 (fr)
EP (2) EP4596543A3 (fr)
JP (1) JP7554739B2 (fr)
KR (2) KR102810978B1 (fr)
CN (1) CN113056271B (fr)
AU (2) AU2019344903B2 (fr)
BR (1) BR112021004919A2 (fr)
CA (1) CA3112411A1 (fr)
CL (1) CL2021000632A1 (fr)
DK (1) DK3852748T3 (fr)
ES (1) ES3051007T3 (fr)
FI (1) FI3852748T3 (fr)
HR (1) HRP20251321T1 (fr)
IL (1) IL281475B2 (fr)
LT (1) LT3852748T (fr)
MA (1) MA53665B1 (fr)
MD (1) MD3852748T2 (fr)
MX (1) MX2021003110A (fr)
PH (1) PH12021550605A1 (fr)
PL (1) PL3852748T3 (fr)
PT (1) PT3852748T (fr)
RS (1) RS67371B1 (fr)
SG (1) SG11202102651SA (fr)
SI (1) SI3852748T1 (fr)
SM (1) SMT202600076T1 (fr)
TW (1) TWI833805B (fr)
WO (1) WO2020061113A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110637011B (zh) 2017-03-15 2024-05-14 奥加诺沃公司 法尼醇x受体激动剂及其用途
AU2018236275B2 (en) 2017-03-15 2022-05-12 Eli Lilly And Company Farnesoid X receptor agonists and uses thereof
HRP20251321T1 (hr) 2018-09-18 2025-12-05 Eli Lilly And Company Agonisti farnezoid x receptora i njihova primjena
US20230060715A1 (en) 2020-01-15 2023-03-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of fxr agonists for treating an infection by hepatitis d virus
BR112022018553A2 (pt) * 2020-03-18 2022-11-29 Metacrine Inc Formulações de um agonista do receptor x farnesoide
MX2022011582A (es) 2020-03-18 2022-12-13 Metacrine Inc Formas cristalinas de un agonista del receptor farnesoide x.
CN120732855A (zh) * 2020-03-18 2025-10-03 伊莱利利公司 用于治疗疾病的法尼醇x受体激动剂
US20240100125A1 (en) 2021-01-14 2024-03-28 Enyo Pharma Synergistic effect of a fxr agonist and ifn for the treatment of hbv infection
CN117320722A (zh) 2021-04-28 2023-12-29 埃尼奥制药公司 使用fxr激动剂作为联合治疗强烈增强tlr3激动剂的作用
CN116554121A (zh) * 2023-05-05 2023-08-08 济南悟通生物科技有限公司 一种2-异丁基噻唑的合成方法

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0010651A (pt) 1999-05-17 2002-03-19 Novo Nordisk As Composto, uso de um composto, composição farmacêutica, e, método para o tratamento e/ou prevenção de distúrbios ou de doenças mediadas por uma ação antagonìstica de glucagon
US6645980B1 (en) 2000-05-25 2003-11-11 Sepracor Inc. Heterocyclic analgesic compounds and methods of use thereof
CA2372887A1 (fr) 1999-05-25 2000-11-30 Sepracor Inc. Composes heterocycliques analgesiques et procedes d'utilisation de ces derniers
US6511980B2 (en) 2000-05-05 2003-01-28 Ortho Mcneil Pharmaceutical, Inc. Substituted diamine derivatives useful as motilin antagonists
AU2001291830A1 (en) 2000-09-25 2002-04-02 Actelion Pharmaceuticals Ltd. Substituted amino-aza-cycloalkanes useful against malaria
FR2815032B1 (fr) 2000-10-10 2003-08-08 Pf Medicament Nouveaux derives d'aminophenyle piperazine ou d'amino phenyle piperide inhibiteurs de proteines prenyl transferase ainsi que leurs preparations
FR2825706B1 (fr) 2001-06-06 2003-12-12 Pf Medicament Nouveaux derives de benzothienyle ou d'indole, leur preparation et leur utilisation comme inhibiteurs de proteines prenyl transferase
FR2839974B1 (fr) 2002-05-24 2004-07-16 Pf Medicament Derives de phenyl-furane ou de phenyl-thiophene,leur preparation et leur application a titre de medicament
AU2003249983A1 (en) 2002-07-18 2004-02-09 Actelion Pharmaceuticals Ltd Piperidines useful for the treatment of central nervous system disorders
JP2006508061A (ja) 2002-09-20 2006-03-09 ファイザー・プロダクツ・インク エストロゲン受容体に対するアミドおよびスルホンアミドリガンド
WO2004046162A2 (fr) 2002-11-14 2004-06-03 The Scripps Research Institute Agonistes fxr non steroidiques
US20050143449A1 (en) 2002-11-15 2005-06-30 The Salk Institute For Biological Studies Non-steroidal farnesoid X receptor modulators and methods for the use thereof
WO2004046323A2 (fr) 2002-11-15 2004-06-03 The Salk Institute For Biological Studies Structure du domaine de fixation du ligand du recepteur farnesoide x et procedes d'utilisation de celle-ci
GB0309781D0 (en) 2003-04-29 2003-06-04 Glaxo Group Ltd Compounds
US7754711B2 (en) 2003-07-30 2010-07-13 Xenon Pharmaceuticals Inc. Pyridazine derivatives and their use as therapeutic agents
US7759348B2 (en) 2003-07-30 2010-07-20 Xenon Pharmaceuticals Inc. Pyridazine derivatives and their use as therapeutic agents
EP3042895A1 (fr) 2003-07-30 2016-07-13 Xenon Pharmaceuticals Inc. Dérivés de la pipérazine et leur utilisation en tant qu'agents thérapeutiques
WO2005058822A1 (fr) 2003-12-17 2005-06-30 Actelion Pharmaceuticals Ltd Cycloalcanes amines substitues
WO2005097760A1 (fr) 2004-03-26 2005-10-20 Rigel Pharmaceuticals, Inc. Composes antiviraux heterocycliques comportant des groupes fonctionnels metabolisables et leurs utilisations
US20050272784A1 (en) 2004-05-07 2005-12-08 Xiaobing Li Inhibitors of bacterial Type III protein secretion systems
JP2006199656A (ja) 2005-01-24 2006-08-03 Kowa Co アミド基を有する環状アミン化合物
MY144229A (en) 2006-01-26 2011-08-15 Xenon Pharmaceuticals Inc Pyridazine derivatives and their use as therapeutic agents
US20100261758A1 (en) 2006-03-28 2010-10-14 Novartis Ag Heterocyclic amides for use as pharmaceuticals
US20080081824A1 (en) 2006-09-29 2008-04-03 Bristol-Myers Squibb Company Substituted piperidines as modulators of chemokine receptor activity
WO2008065500A2 (fr) 2006-11-30 2008-06-05 Pfizer Products Inc. Hétéroaryl amides comme inhibiteurs du transport de la glycine de type i
WO2009076747A1 (fr) 2007-12-19 2009-06-25 Boehringer Ingelheim International Gmbh Inhibiteurs de polymérase virale
WO2010001869A1 (fr) 2008-06-30 2010-01-07 武田薬品工業株式会社 Composé de benzène tétrasubstitué et son utilisation
JP2010077109A (ja) 2008-08-28 2010-04-08 Takeda Chem Ind Ltd 複素環化合物およびその用途
JP2012533553A (ja) 2009-07-15 2012-12-27 アボット・ラボラトリーズ ピロロピリジン系キナーゼ阻害薬
EP2454243A2 (fr) 2009-07-15 2012-05-23 Merck Serono SA Dérivés de tétrazole
FR2963005B1 (fr) 2010-07-23 2012-08-17 Sanofi Aventis Derives d'oxadiazoles et de pyridazines, leur preparation et leur application en therapeutique
SMT201700325T1 (it) 2011-03-23 2017-09-07 Trevena Inc Ligandi del recettore degli oppioidi e metodi per l’uso e la produzione dei medesimi
EP2545964A1 (fr) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Nouveaux composés se liant au fxr (nr1 h4) et modulant son activité
US9492763B2 (en) 2011-07-13 2016-11-15 M. Technique Co., Ltd. Method for producing microparticles having controlled crystallite diameter
RU2543485C2 (ru) 2013-02-26 2015-03-10 Андрей Александрович Иващенко Гетероциклические агонисты рецепторов желчных кислот tgr5, фармацевтическая композиция, способы их получения и применения
GB201316824D0 (en) 2013-09-23 2013-11-06 R & D Vernalis Ltd New Chemical Entities
US10301268B2 (en) 2014-03-13 2019-05-28 The Salk Institute For Biological Studies Analogs of fexaramine and methods of making and using
US10077268B2 (en) 2014-03-13 2018-09-18 Salk Institute For Biological Studies FXR agonists and methods for making and using
US20150258052A1 (en) 2014-03-13 2015-09-17 Salk Institute For Biological Studies Methods of using fexaramine and agents that increase sympathetic nervous system activity to promote browning of white adipose tissue
KR20160133529A (ko) 2014-03-13 2016-11-22 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 펙사라민 유도체 및 이의 제조와 사용 방법
CA2942403A1 (fr) 2014-03-13 2015-09-17 Salk Institute For Biological Studies Agonistes fxr et leurs procedes de fabrication et d'utilisation
WO2016116054A1 (fr) 2015-01-22 2016-07-28 Xiamen University Modulateurs du récepteur farnésoïde x et leurs méthodes d'utilisation
WO2016149111A1 (fr) 2015-03-13 2016-09-22 Salk Institute For Biological Studies Traitement de diabètes auto-immuns latents des adultes à agonistes de récepteur x farnésoïde pour activer les récepteurs intestinaux
WO2017018751A1 (fr) 2015-07-24 2017-02-02 동국대학교 산학협력단 Nouveau composé présentant une activité inhibitrice de blt et composition, destiné à prévenir ou à traiter des maladies inflammatoires, contenant ce dernier en tant que principe actif
US10377717B2 (en) 2015-09-16 2019-08-13 Metacrine, Inc. Farnesoid X receptor agonists and uses thereof
KR20180052678A (ko) * 2015-09-16 2018-05-18 메타크린, 인크. 파네소이드 x 수용체 아고니스트 및 이의 용도
EP3350164A4 (fr) * 2015-09-16 2019-03-27 Metacrine, Inc. Agonistes du récepteur x farnésoïde et leurs utilisations
WO2017049172A1 (fr) 2015-09-16 2017-03-23 Metacrine, Inc. Agonistes du récepteur x farnésoïde et leurs utilisations
CN105477636B (zh) * 2015-10-16 2019-09-17 厦门大学 使用阿维菌素及其衍生物治疗代谢疾病的方法
CN107126419B (zh) 2016-02-26 2020-06-19 石药集团中诺药业（石家庄）有限公司 一种奥贝胆酸片剂及其制备方法
WO2017170182A1 (fr) 2016-03-31 2017-10-05 株式会社Adeka Composition photosensible et nouveau composé
AU2018236275B2 (en) * 2017-03-15 2022-05-12 Eli Lilly And Company Farnesoid X receptor agonists and uses thereof
WO2018170167A1 (fr) 2017-03-15 2018-09-20 Metacrine, Inc. Agonistes du récepteur farnésoïde x et leurs utilisations
WO2018170165A1 (fr) 2017-03-15 2018-09-20 Metacrine, Inc. Agonistes du récepteur farnésoïde x et leurs utilisations
US20200131129A1 (en) 2017-03-15 2020-04-30 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
CN110637011B (zh) 2017-03-15 2024-05-14 奥加诺沃公司 法尼醇x受体激动剂及其用途
CZ2017298A3 (cs) 2017-05-26 2018-12-05 Zentiva, K.S. Amorfní formy obeticholové kyseliny
WO2020060007A1 (fr) 2018-09-17 2020-03-26 엘지전자 주식회사 Procédé et dispositif sans fil pour gérer une session de pdu dans une communication mobile 5g
CN113056264A (zh) 2018-09-18 2021-06-29 梅塔科林公司 法尼醇x受体激动剂及其用途
HRP20251321T1 (hr) 2018-09-18 2025-12-05 Eli Lilly And Company Agonisti farnezoid x receptora i njihova primjena
WO2020061116A1 (fr) 2018-09-18 2020-03-26 Metacrine, Inc. Agonistes du récepteur farnésoïde x et leurs utilisations
WO2020061114A1 (fr) 2018-09-18 2020-03-26 Metacrine, Inc. Agonistes du récepteur farnésoïde x pour le traitement d'une maladie
WO2020061118A1 (fr) 2018-09-18 2020-03-26 Metacrine, Inc. Agonistes du récepteur farnésoïde x et leurs utilisations
JP2022500395A (ja) 2018-09-18 2022-01-04 メタクリン，インク． ファルネソイドｘ受容体アゴニストの結晶形態
WO2020061117A1 (fr) 2018-09-18 2020-03-26 Metacrine, Inc. Agonistes du récepteur farnésoïde x et leurs utilisations
CN120732855A (zh) 2020-03-18 2025-10-03 伊莱利利公司 用于治疗疾病的法尼醇x受体激动剂
BR112022018553A2 (pt) 2020-03-18 2022-11-29 Metacrine Inc Formulações de um agonista do receptor x farnesoide
MX2022011582A (es) 2020-03-18 2022-12-13 Metacrine Inc Formas cristalinas de un agonista del receptor farnesoide x.

Also Published As

Publication number Publication date
US11773094B2 (en) 2023-10-03
SG11202102651SA (en) 2021-04-29
TW202024052A (zh) 2020-07-01
JP2022500392A (ja) 2022-01-04
PH12021550605A1 (en) 2021-10-04
MA53665B1 (fr) 2025-09-30
WO2020061113A1 (fr) 2020-03-26
BR112021004919A2 (pt) 2021-06-01
CL2021000632A1 (es) 2021-07-23
KR20250073553A (ko) 2025-05-27
SMT202600076T1 (it) 2026-03-09
EP4596543A2 (fr) 2025-08-06
IL281475B1 (en) 2024-12-01
ES3051007T3 (en) 2025-12-23
AU2019344903A1 (en) 2021-05-13
EP3852748B1 (fr) 2025-09-03
MD3852748T2 (ro) 2026-01-31
PL3852748T3 (pl) 2025-12-01
PT3852748T (pt) 2025-10-24
SI3852748T1 (sl) 2025-11-28
LT3852748T (lt) 2025-11-25
FI3852748T3 (fi) 2025-10-22
KR102810978B1 (ko) 2025-05-23
US20200102308A1 (en) 2020-04-02
RS67371B1 (sr) 2025-11-28
TWI833805B (zh) 2024-03-01
JP7554739B2 (ja) 2024-09-20
US11084817B2 (en) 2021-08-10
AU2025203804A1 (en) 2025-06-12
IL281475A (en) 2021-04-29
IL281475B2 (en) 2025-04-01
US20210395253A1 (en) 2021-12-23
CA3112411A1 (fr) 2020-03-26
US20250289821A1 (en) 2025-09-18
EP4596543A3 (fr) 2025-10-15
MX2021003110A (es) 2021-05-13
AU2019344903B2 (en) 2025-02-27
KR20210076910A (ko) 2021-06-24
US20230382913A1 (en) 2023-11-30
HRP20251321T1 (hr) 2025-12-05
CN113056271B (zh) 2024-10-29
DK3852748T3 (da) 2025-10-06
CN113056271A (zh) 2021-06-29
EP3852748A4 (fr) 2022-05-18
EP3852748A1 (fr) 2021-07-28

Similar Documents

Publication Publication Date Title
EP3852748A4 (fr) Agonistes du récepteur farnésoïde x et leurs utilisations
EP3350165A4 (fr) Agonistes du récepteur x farnésoïde et leurs utilisations
EP3350166A4 (fr) Agonistes du récepteur x farnésoïde et leurs utilisations
EP3852736A4 (fr) Agonistes du récepteur farnésoïde x et leurs utilisations
EP3350164A4 (fr) Agonistes du récepteur x farnésoïde et leurs utilisations
EP3350158A4 (fr) Agonistes du récepteur x farnésoïde et leurs utilisations
MA56480A (fr) Agonistes du récepteur glp-1 et leurs utilisations
DK3609888T3 (da) Farnesoid x-receptor-agonister og anvendelser deraf
MA54555A (fr) Agonistes de glp-1r et leurs utilisations
IL283550A (en) Chemically-modified rnai constructs and uses thereof
EP3810182A4 (fr) Néoantigènes et leurs utilisations
EP3768664A4 (fr) Inhibiteurs de shp2 et leurs utilisations
EP3891183A4 (fr) Anticorps anti-claudine et leurs utilisations
EP3727371A4 (fr) Inhibiteurs d'hétéromères gpcr et leurs utilisations
EP3732191A4 (fr) Récepteurs antigéniques chimériques améliorés et leurs utilisations
EP3759143A4 (fr) Anticorps anti-tigit et leurs utilisations
MA50618A (fr) Polyrhérapies et leurs utilisations
EP3658163A4 (fr) Récepteurs antigéniques chimériques améliorés et leurs utilisations
EP3790861A4 (fr) Compositions sénolytiques et utilisations associées
MA43417A (fr) Agonistes améliorés du récepteur de l'apéline (apj) et leurs utilisations
EP3600287A4 (fr) Inhibiteurs de réseaux de kinase et leurs utilisations
EP3790586A4 (fr) Anticorps anti-dll3 et leurs utilisations
MA49133A (fr) Anticorps agonistes anti-btla et leurs utilisations
EP3870162A4 (fr) Inhibiteurs de ssao et leurs utilisations
EP3850012A4 (fr) Anticorps anti-tnfrsf9 et leurs utilisations